Roche Pays $2.4 Billion For Rest Of Cancer Expert Foundation Medicine

Jun 19, 2018, 09:42 AM by Michael Croft

Reuters | Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.

June 19, 2018 | Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising its bet on the U.S. genomic profiling group's ability to personalize cancer care. Reuters